Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.8K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.8K
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.8K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Introduction to Hemostasis01:05

Introduction to Hemostasis

16.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
16.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet Registry.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Real-World Outcomes of Prophylaxis With rIX-FP in Germany: A Prospective, Non-Interventional Study in Haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

[Invasive mechanical ventilation: indications and alternatives : Systematic evaluation of the evidence and recommendations for clinical practice from the S3 guidelines "invasive mechanical ventilation and the use of extracorporeal procedures in acute respiratory failure"].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2026
Same author

When and How to Start Prophylaxis in Children with Hemophilia.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026
Same author

Inhibitor development according to FVIII concentrates in previously untreated patients with severe hemophilia A: update from the PedNet registry.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting.

Therapeutic advances in hematology·2026

Related Experiment Video

Updated: Mar 24, 2026

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.6K

[Haemostatic disorders in children].

Karin Kurnik1, Christoph Bidlingmaier, Sebastian Hütker

  • 1Priv.-Doz. Dr. med. Karin Kurnik, Kinderklinik im Dr. von Haunerschen Kinderspital Klinikum der Universität München, Lindwurmstr. 4, 80337 München, Karin.Kurnik@med.uni-muenchen.de.

Hamostaseologie
|March 19, 2016
PubMed
Summary

Hemorrhagic and thrombotic events affect all ages, often stemming from congenital or acquired disorders. Understanding age-specific coagulation is crucial for diagnosing and managing these bleeding and clotting complications in children.

Keywords:
Haemostatic disordershaemorrhagic disorders in childrentherapythrombotic disorders in children

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K

Related Experiment Videos

Last Updated: Mar 24, 2026

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.6K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.7K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K

Area of Science:

  • Pediatric Hematology
  • Hemostasis and Thrombosis
  • Clinical Coagulation

Background:

  • Hemorrhagic and thrombotic events are observed in both pediatric and adult populations.
  • Causes include congenital and acquired disorders.
  • Inherited thrombotic disorders, particularly with external risk factors, manifest predominantly in newborns and adolescents.

Purpose of the Study:

  • To highlight the importance of age-specific coagulation properties.
  • To guide the interpretation of clinical and laboratory findings in children.
  • To improve the management of hemorrhagic and thrombotic complications in pediatric patients.

Main Methods:

  • This study is a review of existing literature and clinical guidelines.
  • It focuses on the age-dependent characteristics of the coagulation system.
  • Analysis of clinical presentations and laboratory results in pediatric cohorts.

Main Results:

  • Coagulation profiles and risks differ significantly between neonates, children, and adults.
  • External risk factors play a critical role in the manifestation of inherited thrombotic disorders during specific pediatric age periods.
  • Accurate interpretation requires consideration of developmental hemostasis.

Conclusions:

  • Awareness of age-specific coagulation is essential for accurate diagnosis and treatment.
  • Optimal care for children with bleeding or clotting disorders necessitates understanding these age-related nuances.
  • This knowledge aids in differentiating and managing hemorrhagic versus thrombotic conditions in pediatrics.